Anna Stengel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Stengel has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Manja Meggendorfer
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich 81377, Germany
21 shared publicationsWolfgang Kern
MLL Munich Leukemia Laboratory Munich Germany
19 shared publicationsTorsten Haferlach
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich 81377, Germany
18 shared publicationsClaudia Haferlach
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich 81377, Germany
17 shared publications- Claudia Haferlach
MLL Munich Leukemia Laboratory, Munich, Germany
8 shared publications - Wencke Walter
MLL Munich Leukemia Laboratory, Munich, Germany
8 shared publications
Latest Publications
- 13 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 2067-2070
Subclonal MECOM rearrangements in myeloid neoplasms: enriched for TP53 mutations and adverse outcome
- 13 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 2067-2070
Subclonal MECOM rearrangements in myeloid neoplasms: enriched for TP53 mutations and adverse outcome
- Open Access
- 12 May 2026
- Published by Wiley in HemaSphere
- Vol. 10 (5)
The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
- 12 May 2026
- Published by Wiley in HemaSphere
- Vol. 10 (5)
Open AccessThe rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
- 15 May 2025
- Published by Elsevier in Cancer Genetics
- Vol. 294-295, 181-183
Potential factors underlying the progression of RUNX1-mutated MDS to AML
- 15 May 2025
- Published by Elsevier in Cancer Genetics
- Vol. 294-295, 181-183
Potential factors underlying the progression of RUNX1-mutated MDS to AML
- Open Access
- 3 March 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 29
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity
- 3 March 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 29
Open AccessMyeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity
- Open Access
- 1 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 4125-4128
Characterization of cases with the rare cytogenetic abnormality i(7)(p10) reveals an association with IDH2-mutated AML
- 1 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 4125-4128
Open AccessCharacterization of cases with the rare cytogenetic abnormality i(7)(p10) reveals an association with IDH2-mutated AML
- Open Access
- 15 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (18) , 5540-5548
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
Several clinical and genetic factors impact overall survival (OS) in myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), including complex karyotype (CK), TP53 allelic state, and blast count. We analyzed the interplay of these factors by performing Cox regression analysis and by determining the frequency of TP53 single-hit (sh) and double-hit (dh) events and OS in MDS (n = 747) with <5% blasts, with ≥5% but <10% blasts, and ≥10% but <20% blasts and AML (n = 772). MDS with <5% blasts showed the best outcome, followed by with ≥5% but <10% blasts, and ≥10% but <20% blasts, and AML (median OS: 75, 54, 27, and 18 months, respectively). The same hierarchy was observed when each subgroup was divided into TP53sh, TP53dh, and without TP53 alterations (alt), revealing a dismal outcome of TP53dh in all subgroups (17, 10, 8, and 1 month[s], respectively). MDS with <5% blasts differed from the other subgroups by showing predominantly TP53sh (76% of TP53alt cases), and by an independent adverse impact of CK on OS (hazard ratio, 5.2; P < .001). The remaining subgroups displayed many similarities, with TP53dh found at high frequencies (67%, 91%, and 71%, respectively) and only TP53alt but not CK independently influencing OS, and TP53dh showing the strongest influence. When the total cohort was split based on TP53 state, only the blast count and not CK had an independent adverse impact on OS in all subgroups. Thus, TP53dh is the strongest prognostic factor, further supporting its integration into risk stratification guidelines and classification as a separate entity. However, the blast count also influences OS independent of TP53 state, whereas CK plays a minor prognostic role.
- 15 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (18) , 5540-5548
Open AccessInterplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
Several clinical and genetic factors impact overall survival (OS) in myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), including complex karyotype (CK), TP53 allelic state, and blast count. We analyzed the interplay of these factors by performing Cox regression analysis and by determining the frequency of TP53 single-hit (sh) and double-hit (dh) events and OS in MDS (n = 747) with <5% blasts, with ≥5% but <10% blasts, and ≥10% but <20% blasts and AML (n = 772). MDS with <5% blasts showed the best outcome, followed by with ≥5% but <10% blasts, and ≥10% but <20% blasts, and AML (median OS: 75, 54, 27, and 18 months, respectively). The same hierarchy was observed when each subgroup was divided into TP53sh, TP53dh, and without TP53 alterations (alt), revealing a dismal outcome of TP53dh in all subgroups (17, 10, 8, and 1 month[s], respectively). MDS with <5% blasts differed from the other subgroups by showing predominantly TP53sh (76% of TP53alt cases), and by an independent adverse impact of CK on OS (hazard ratio, 5.2; P < .001). The remaining subgroups displayed many similarities, with TP53dh found at high frequencies (67%, 91%, and 71%, respectively) and only TP53alt but not CK independently influencing OS, and TP53dh showing the strongest influence. When the total cohort was split based on TP53 state, only the blast count and not CK had an independent adverse impact on OS in all subgroups. Thus, TP53dh is the strongest prognostic factor, further supporting its integration into risk stratification guidelines and classification as a separate entity. However, the blast count also influences OS independent of TP53 state, whereas CK plays a minor prognostic role.
- Open Access
- 8 February 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (13) , 2952-2956
Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
- 8 February 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (13) , 2952-2956
Open AccessSpecific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
- Open Access
- 16 December 2022
- Published by Springer Nature in Leukemia
- Vol. 37 (1) , 252
Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
- 16 December 2022
- Published by Springer Nature in Leukemia
- Vol. 37 (1) , 252
Open AccessCorrection: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 2990-2991
RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
Background: Mutations in the myeloid transcription factor RUNX1 are frequently detected in AML and MDS. Differences have been described regarding additional cyt
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 2990-2991
Open AccessRUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
Background: Mutations in the myeloid transcription factor RUNX1 are frequently detected in AML and MDS. Differences have been described regarding additional cyt
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 3405-3406
IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
Background: Mutations in the gene coding for isocitrate dehydrogenase isoform 2 (IDH2) frequently occur in acute myeloid leukemia (AML). IDH2 is an interesting
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 3405-3406
Open AccessIDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
Background: Mutations in the gene coding for isocitrate dehydrogenase isoform 2 (IDH2) frequently occur in acute myeloid leukemia (AML). IDH2 is an interesting